S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:EVFM

Evofem Biosciences Price Target, Predictions & Analyst Ratings

$0.70
-0.01 (-1.41 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$0.68
$0.71
50-Day Range
$0.67
$0.89
52-Week Range
$0.65
$5.53
Volume2.52 million shs
Average Volume6.66 million shs
Market Capitalization$108.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.33

Evofem Biosciences (NASDAQ:EVFM) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 2 Analyst Ratings

Analyst Price Target Consensus

$1.75

High PT$2.50
Average PT$1.75
Low PT$1.00
TypeCurrent
10/23/20 to 10/23/21
1 Month Ago
9/23/20 to 9/23/21
3 Months Ago
7/25/20 to 7/25/21
1 Year Ago
10/24/19 to 10/23/20
Consensus Rating
Hold
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1.75$3.33$9.25$9.71
Price Target Upside150.72% Upside143.83% Upside288.03% Upside179.64% Upside
Get Evofem Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Evofem Biosciences (NASDAQ:EVFM) vs. Its Competitors

TypeEvofem BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.73
2.56
Consensus RatingHoldBuyBuy
Price Target Upside146.40% Upside6.68% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
257
70.22%
Underperform Votes
109
29.78%
Avg. Outperform Votes
178
67.42%
Avg. Underperform Votes
86
32.58%
Avg. Outperform Votes
831
69.48%
Avg. Underperform Votes
365
30.52%

Evofem Biosciences (NASDAQ:EVFM) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/21/2021HC Wainwright
Reiterated RatingBuy$4.00 ➝ $2.50+249.16%
10/14/2021Morgan Stanley
DowngradeEqual Weight ➝ Underweight
10/1/2020Stifel Nicolaus
Initiated CoverageBuy$5.00+109.20%
8/10/2020Oppenheimer
Leland Gershell
Boost Price TargetOutperform$18.00 ➝ $25.00+753.24%
6/8/2020Piper Sandler
Initiated CoverageOverweight$11.00+232.33%
5/31/2020Royal Bank of Canada
Reiterated RatingBuy
5/22/2020Cantor Fitzgerald
Louise Chen
Reiterated RatingBuy$9.00+80.36%
(Data available from 10/23/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Evofem Biosciences (NASDAQ:EVFM) Analyst Ratings Frequently Asked Questions

What is Evofem Biosciences's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Evofem Biosciences stock is Hold based on the current 1 sell rating and 1 buy rating for EVFM. The average twelve-month price target for Evofem Biosciences is $1.75 with a high price target of $2.50 and a low price target of $1.00. Learn more on EVFM's analyst rating history

Do Wall Street analysts like Evofem Biosciences more than its competitors?

Analysts like Evofem Biosciences stock less than the stock of other Medical companies. The consensus rating for Evofem Biosciences is Hold while the average consensus rating for medical companies is Buy. Learn more on how EVFM compares to other companies

Do MarketBeat users like Evofem Biosciences more than its competitors?

MarketBeat users like Evofem Biosciences stock more than the stock of other Medical companies. 70.22% of MarketBeat users gave Evofem Biosciences an outperform vote while medical companies recieve an average of 67.42% outperform votes by MarketBeat users.

Is Evofem Biosciences being downgraded by Wall Street analysts?

Over the previous 90 days, Evofem Biosciences's stock had 1 downgrade by analysts.

Does Evofem Biosciences's stock price have much upside?

According to analysts, Evofem Biosciences's stock has a predicted upside of 130.48% based on their 12-month price targets.

What analysts cover Evofem Biosciences?

Evofem Biosciences has been rated by HC Wainwright, and Morgan Stanley in the past 90 days.

This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.